AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22688444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg (K1)
Number of subjects: 120
Study 22688444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 3 mg/kg (K2)
Number of subjects: 120
Study 22688444 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 1 drop/5 kg
Number of subjects: 120
Study 20660044 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 6
Study 20660044 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy
Number of subjects: 6
Study 20660044 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin profile
Number of subjects: 6
Study 18554819 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic personalised feedback and social norms information on drinking behaviour (12-week duration)
Number of subjects: 506
Study 18554819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 506
Study 18554819 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic personalised feedback and social norms information
Number of subjects: 506
Study 16159570 — intervention group
Group type: COMPARATOR
Intervention: Huobahuagen Tablets (5 tablets po t.i.d.)
Number of subjects: 62
Study 16159570 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 to 300 mg po q.d.)
Number of subjects: 62
Study 11943447 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group-developed consent document
Number of subjects: 1092
Study 11943447 — intervention group
Group type: COMPARATOR
Intervention: Investigator-developed consent document
Number of subjects: 1092
Study 10067004 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment of relatives of patients with schizophrenia
Number of subjects: 126
Study 8826921 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide-flutamide androgen inhibition therapy
Number of subjects: 173
Study 8826921 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonally treated prostates
Number of subjects: 173
Study 2147599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered orally for 6 months (1600-2400 mg/day)
Number of subjects: 27
Study 2147599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered by intravenous infusion (500-1000 mg/day)
Number of subjects: 27
Study 2147599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered by intramuscular injection (100-200 mg/day)
Number of subjects: 27
Study 2147599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP) administered by mouth (1600-2400 mg/day)
Number of subjects: 27
Study 2147599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloromethylene bisphosphonate (C12MBP)
Number of subjects: 27
Study 6105342 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (continuous, oral administration, dosage not specified)
Number of subjects: 0
Study 31856425 — intervention group
Group type: EXPERIMENTAL
Intervention: atomoxetine 18 mg daily
Number of subjects: 50
Study 31856425 — intervention group
Group type: COMPARATOR
Intervention: midodrine 5 mg twice daily
Number of subjects: 50
Study 31856425 — intervention group
Group type: EXPERIMENTAL
Intervention: combination treatment (atomoxetine and midodrine)
Number of subjects: 50
Study 31156144 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuan-Sin-Yin treatment (Group K)
Number of subjects: 17
Study 31156144 — intervention group
Group type: COMPARATOR
Intervention: No Kuan-Sin-Yin treatment (Group NK)
Number of subjects: 17
Study 28984747 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day diazepam treatment
Number of subjects: 26
Study 28984747 — intervention group
Group type: COMPARATOR
Intervention: 10-day diazepam treatment
Number of subjects: 26
Study 25352438 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising energy deficit group (ED2; -22 ± 3%)
Number of subjects: 34
Study 25352438 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising energy deficit group (ED3; -42 ± 3%)
Number of subjects: 34
Study 25352438 — intervention group
Group type: COMPARATOR
Intervention: Exercising control (EXCON)
Number of subjects: 34
Study 25352438 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising energy deficit group (ED1; -8 ± 2%)
Number of subjects: 34
Study 25352438 — intervention group
Group type: EXPERIMENTAL
Intervention: Average percent energy deficit
Number of subjects: 34
Study 23548195 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing pre-pain rehabilitation intervention (MIP)
Number of subjects: 160
Study 23548195 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 160
Study 22289549 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day rosuvastatin
Number of subjects: 36
Study 22289549 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/day atorvastatin
Number of subjects: 36
Study 19349559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1108
Study 19349559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1108
Study 16432086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside tests (7-variable clinical model, D-dimer test, alveolar dead-space fraction)
Number of subjects: 398
Study 16432086 — intervention group
Group type: COMPARATOR
Intervention: Ventilation-perfusion (V/Q) scan
Number of subjects: 398
Study 16432086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside tests (with at least 2 negative results)
Number of subjects: 398
Study 16432086 — intervention group
Group type: COMPARATOR
Intervention: 7-variable clinical model and D-dimer test
Number of subjects: 398
Study 15134181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV)
Number of subjects: 142
Study 15134181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 142
Study 11394467 — intervention group
Group type: EXPERIMENTAL
Intervention: Device for measuring gripping forces and applied moments during hand tool use
Number of subjects: 0
Study 9608414 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg D-cycloserine
Number of subjects: 0
Study 9608414 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher medication dosage or long-term treatment
Number of subjects: 0
Study 8080299 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mitomycin C and/or 5-fluorouracil
Number of subjects: 1177
Study 8080299 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1177
Study 2513173 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 7
Study 2513173 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 100 micrograms
Number of subjects: 7
Study 2513173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 4448416 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrate alone
Number of subjects: 9
Study 4448416 — intervention group
Group type: COMPARATOR
Intervention: Concentrate plus heparin
Number of subjects: 9
Study 4448416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 9
Study 31102457 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil (PDE5 inhibitor) for 8 weeks in mice
Number of subjects: 2
Study 31102457 — intervention group
Group type: EXPERIMENTAL
Intervention: sildenafil (PDE5 inhibitor) for 4 weeks in humans
Number of subjects: 2
Study 31102457 — intervention group
Group type: COMPARATOR
Intervention: vehicle (control) for 8 weeks in mice
Number of subjects: 2
Study 31102457 — intervention group
Group type: COMPARATOR
Intervention: placebo for 4 weeks in humans
Number of subjects: 2
Study 28077344 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐FABP in DKA patients at presentation
Number of subjects: 75
Study 28077344 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐FABP in DKA patients after acidosis correction (at hour 36)
Number of subjects: 75
Study 28077344 — intervention group
Group type: COMPARATOR
Intervention: Troponin I and CK‐MB levels in all groups
Number of subjects: 75
Study 25227729 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient coarse PM (CAP) (76.2 ± 51.5 μg/m(3))
Number of subjects: 32
Study 25227729 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 32
Study 22999065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet + virgin olive oil
Number of subjects: 110
Study 22999065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet + nuts
Number of subjects: 110
Study 22999065 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 110
Study 21442804 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with massage
Number of subjects: 45
Study 21442804 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Dexamethasone, Methotrexate, Prednisone)
Number of subjects: 45
Study 19635128 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based problem solving through the internet (self‐examination therapy) without a coach
Number of subjects: 500
Study 19635128 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based problem solving through the internet (self‐examination therapy) with the possibility to ask help from a coach on the initiative of the respondent (on demand, by email)
Number of subjects: 500
Study 19635128 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based problem solving through the internet (self‐examination therapy) with weekly scheduled contacts initiated by a coach (once per week, by email)
Number of subjects: 500
Study 19635128 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly scheduled contacts initiated by a coach, but no web‐based intervention
Number of subjects: 500
Study 19635128 — intervention group
Group type: EXPERIMENTAL
Intervention: information only (through the internet)
Number of subjects: 500
Study 19635128 — intervention group
Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 500
Study 16968364 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) program
Number of subjects: 107
Study 16968364 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 107
Study 14551133 — intervention group
Group type: EXPERIMENTAL
Intervention: hyper-CVAD and imatinib mesylate
Number of subjects: 20
Study 11530042 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT-trabeculectomy-trabeculectomy (ATT) sequence
Number of subjects: 657
Study 11530042 — intervention group
Group type: EXPERIMENTAL
Intervention: trabeculectomy-ALT-trabeculectomy (TAT) sequence
Number of subjects: 657
Study 11530042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment sequences
Number of subjects: 657
Study 9240732 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 300 mg
Number of subjects: 105
Study 9240732 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate 300 mg
Number of subjects: 105
Study 9240732 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 150 mg
Number of subjects: 105
Study 9240732 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 600 mg
Number of subjects: 105
Study 9240732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 7901952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone (30 mg)
Number of subjects: 12
Study 7901952 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg)
Number of subjects: 12
Study 3630823 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-containing IUDs (Nova-T, MLCu250, MLCu375)
Number of subjects: 97
Study 3630823 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene stimulation
Number of subjects: 97
Study 31926321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 343
Study 31926321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation (MM)
Number of subjects: 343
Study 31926321 — intervention group
Group type: COMPARATOR
Intervention: Education Control (EDU)
Number of subjects: 343
Study 31397127 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with umbilical therapy
Number of subjects: 120
Study 31397127 — intervention group
Group type: COMPARATOR
Intervention: Montmorillonite powder (smecta)
Number of subjects: 120
Study 28169553 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus health promotion intervention
Number of subjects: 0
Study 25562712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.03 mg/kg/day
Number of subjects: 68
Study 25562712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox) 0.06 mg/kg/day
Number of subjects: 68
Study 25562712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (Ox)
Number of subjects: 68
Study 25562712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 68
Study 23280362 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflection training (different version of DCCS with corrective feedback)
Number of subjects: 0
Study 23280362 — intervention group
Group type: COMPARATOR
Intervention: Corrective feedback alone or mere practice with the task (control conditions)
Number of subjects: 0
Study 23280362 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflection training (shortened 15min version)
Number of subjects: 0
Study 21729487 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized diet (fermented soyabean and vitamin C-rich fruit)
Number of subjects: 252
Study 21729487 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 252
Study 18304907 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg/day, adjustable)
Number of subjects: 110
Study 18304907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16996843 — intervention group
Group type: EXPERIMENTAL
Intervention: Four IA courses at monthly intervals
Number of subjects: 22
Study 16996843 — intervention group
Group type: COMPARATOR
Intervention: One IA course only
Number of subjects: 22
Study 12850861 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10mg/day
Number of subjects: 75
Study 12850861 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once a week
Number of subjects: 75
Study 12850861 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric alendronate 70 mg per week
Number of subjects: 75
Study 10369728 — intervention group
Group type: COMPARATOR
Intervention: 1alpha-hydroxyvitamin D3 (1alpha(OH)D3) 1.0 microg/day
Number of subjects: 79
Study 10369728 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens 0.625 mg/day
Number of subjects: 79
Study 10369728 — intervention group
Group type: COMPARATOR
Intervention: Combination of conjugated estrogens + 1alpha(OH)D3
Number of subjects: 79
Study 10369728 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 79
Study 8658369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 160 micrograms
Number of subjects: 20
Study 8658369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 240 micrograms
Number of subjects: 20
Study 8658369 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 40 micrograms
Number of subjects: 20
Study 8658369 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 80 micrograms
Number of subjects: 20
Study 8658369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1867125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 0
Study 1867125 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0
Study 1867125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7055528 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg i.v.
Number of subjects: 0
Study 7055528 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.6 mg i.v.
Number of subjects: 0
Study 7055528 — intervention group
Group type: COMPARATOR
Intervention: Previous work comparison
Number of subjects: 0
Study 30957141 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposeful sandbagging group
Number of subjects: 77
Study 30957141 — intervention group
Group type: EXPERIMENTAL
Intervention: Word Memory EII
Number of subjects: 77
Study 30957141 — intervention group
Group type: EXPERIMENTAL
Intervention: Three Letters EII
Number of subjects: 77
Study 30957141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 30957141 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score ≤1st percentile
Number of subjects: 77
Study 30640204 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T/3TC/EFV
Number of subjects: 536
Study 30640204 — intervention group
Group type: COMPARATOR
Intervention: TDF/3TC/EFV
Number of subjects: 536
Study 30223808 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based care with guardian-administered intramuscular injections
Number of subjects: 14
Study 30223808 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 14
Study 26919207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin plus prednisolone
Number of subjects: 33
Study 26919207 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 33
Study 24456512 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session, 4-week lifestyle intervention
Number of subjects: 95
Study 24456512 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 95
Study 22833440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 60
Study 22833440 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 60
Study 20955955 — intervention group
Group type: EXPERIMENTAL
Intervention: GPX instruments (21-mm-long teeth)
Number of subjects: 50
Study 20955955 — intervention group
Group type: EXPERIMENTAL
Intervention: GPX and xylol as solvent (21-mm-long teeth)
Number of subjects: 50
Study 20955955 — intervention group
Group type: EXPERIMENTAL
Intervention: GPX instruments (25-mm-long teeth)
Number of subjects: 50
Study 20955955 — intervention group
Group type: EXPERIMENTAL
Intervention: GPX and xylol as solvent (25-mm-long teeth)
Number of subjects: 50
Study 20955955 — intervention group
Group type: COMPARATOR
Intervention: Hand files and xylol as solvent
Number of subjects: 50
Study 17028126 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC1W (1 week of omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 909
Study 17028126 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC2W (2 weeks of omeprazole, amoxicillin, and clarithromycin)
Number of subjects: 909
Study 17028126 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole and amoxicillin (2 weeks)
Number of subjects: 909
Study 17028126 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC2W
Number of subjects: 909
Study 17028126 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC1W
Number of subjects: 909
Study 11092110 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate Easyhaler (BDP-EH)
Number of subjects: 79
Study 11092110 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbohaler (BUD-TH)
Number of subjects: 79
Study 11092110 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 79
Study 9305555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 15
Study 9305555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 15
Study 9305555 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 15
Study 8348786 — intervention group
Group type: EXPERIMENTAL
Intervention: I2-NaF solution; administered six times to mothers' dentition.
Number of subjects: 48
Study 8348786 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution; administered six times to mothers' dentition.
Number of subjects: 48
Study 3786637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.15 mg)
Number of subjects: 10
Study 3786637 — intervention group
Group type: COMPARATOR
Intervention: Placebo controls
Number of subjects: 10
Study 28844767 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flexion Mobile-Bearing TKA
Number of subjects: 92
Study 28844767 — intervention group
Group type: COMPARATOR
Intervention: High-Flexion Fixed-Bearing TKA
Number of subjects: 92
Study 27120807 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus Bev
Number of subjects: 289
Study 27120807 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 289
Study 27120807 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 289
Study 25594352 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuFVIIa infusion
Number of subjects: 84
Study 25594352 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 84
Study 23615461 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐CHOP‐14 (intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 2 mg, rituximab 375 mg/m² on day 1, oral prednisolone 100 mg on days 1‐5, administered every 14 days for six cycles, followed by two further infusions of rituximab 375 mg/m² on day 1 every 14 days)
Number of subjects: 1080
Study 23615461 — intervention group
Group type: COMPARATOR
Intervention: R‐CHOP‐21 (intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², rituximab 375 mg/m² on day 1, oral prednisolone 40 mg/m² on days 1‐5, administered every 21 days for a total of eight cycles)
Number of subjects: 1080
Study 23615461 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐CHOP‐14
Number of subjects: 1080
Study 23615461 — intervention group
Group type: COMPARATOR
Intervention: R‐CHOP‐21
Number of subjects: 1080
Study 20309699 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern drug therapy
Number of subjects: 0
Study 20309699 — intervention group
Group type: COMPARATOR
Intervention: Controlled drugs trials
Number of subjects: 0
Study 20309699 — intervention group
Group type: COMPARATOR
Intervention: Practice registries
Number of subjects: 0
Study 18845978 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 11
Study 18845978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16619563 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 KE of OK-432 (arm A)
Number of subjects: 38